Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)

• Company Description    Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 483

• Price / Volume Information    Yesterday's Closing Price: $22.21 Daily Weekly Monthly 20 Day Moving Average: 2,598,738 shares Shares Outstanding: 101.47 (millions) Market Capitalization: $2,253.76 (millions) Beta: 2.40 52 Week High: $35.25 52 Week Low: $13.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.62% -17.83% 12 Week 24.64% 19.47% Year To Date -10.44% -21.72%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 238 Main Street - Cambridge,MA 02142 USA ph: 857-327-8775 fax: - investors@beamtx.com https://beamtx.com

• General Corporate Information    Officers John Evans - Chief Executive Officer and Director Sravan Emany - Chief Financial Officer Bethany Cavanagh - Senior Vice President; Finance and Treasurer Graham Cooper - Director Chirfi Guindo - Director Peer Information Beam Therapeutics Inc. (CORR.) Beam Therapeutics Inc. (RSPI) Beam Therapeutics Inc. (CGXP) Beam Therapeutics Inc. (BGEN) Beam Therapeutics Inc. (GTBP) Beam Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07373V105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/24/26 Share - Related Items Shares Outstanding: 101.47 Most Recent Split Date: (:1) Beta: 2.40 Market Capitalization: $2,253.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.13 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 7.88% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/24/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.33 Price/Cash Flow: - Price / Sales: 40.46 EPS Growth vs. Year Ago Period: 5.98% vs. Previous Quarter: -10.00% Sales Growth vs. Year Ago Period: -32.03% vs. Previous Quarter: 14.55% ROE 09/30/25 - -42.86 06/30/25 - -43.15 03/31/25 - -44.24 ROA 09/30/25 - -31.45 06/30/25 - -31.06 03/31/25 - -30.97 Current Ratio 09/30/25 - 6.02 06/30/25 - 6.75 03/31/25 - 8.81 Quick Ratio 09/30/25 - 6.02 06/30/25 - 6.75 03/31/25 - 8.81 Operating Margin 09/30/25 - -744.41 06/30/25 - -661.31 03/31/25 - -609.24 Net Margin 09/30/25 - -744.41 06/30/25 - -661.31 03/31/25 - -609.24 Pre-Tax Margin 09/30/25 - -744.41 06/30/25 - -661.31 03/31/25 - -609.18 Book Value 09/30/25 - 9.52 06/30/25 - 10.35 03/31/25 - 11.17 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©